[Skip to Content]

Upstate Active Clinical Trials

Study Title:

Astagraf XL® to Understand the Impact of Immunosuppression on De Novo DSA Development and Chronic Immune Activation in Kidney Transplantation (ASTOUND)

What is the purpose of the study? (in Layman's terms, please describe the study)

The main purpose of the study is to better understand how Astagraf XL, when taken with other medicines that are routinely used for kidney transplantation, may stop the development of a substance in the blood that can cause long-term damage to your transplanted kidney. To do this, this study will compare the safety and effectiveness of Astagraf XL to that of immediate-release tacrolimus medication, another medicine that has been approved by the FDA as an anti-rejection treatment

Upstate Institutional Review Board (IRB) Number:

943496

Study Phase:

Phase IV

Patient Age Group:

Adults

Principal Investigator:

Mark Laftavi

Who can I contact for more information?

Name: Linda J Ellinwood, RN
Phone: 315-464-1852
Email: ellinwol@upstate.edu

Return to Previous Page || Search Again

Top